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Interventional Cardiology
SES Superior to PES in Patients With Small Vessel Disease
The SIRTAX trial was a randomized controlled trial comparing the safety andefficacy of sirolimus-eluting stents (SES) and paclitaxel-eluting stents (PES). In
the overall study, SES provided lower late luminal loss, which translated into lower
rates of clinical and angiographic restenosis. The current study examines the impact of
vessel size on outcomes, notably 2.75 mm. In these small vessels, 2-year major
adverse cardiac events (MACE) was 2 times higher in the PES group, driven chiefly by
a 69% reduction in the risk of target lesion revascularization (TLR) in favor of SES.
Compared with PES, SES more effectively reduce MACE and TLR in small-vessel
disease. Differences between SES and PES appear less pronounced in patients with
large- and mixed-vessel disease. See page 1123. See figure.
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Antiplatelet Therapy
Poor Responders to Clopidogrel Respond Well to Ticlopidine
Depending on the criteria, 10% to 30% of patients may be poor responders toclopidogrel. Campo and colleagues investigated whether or not this was a class
effect with thienopyridines or was specific to clopidogrel by sequentially giving both
drugs to patients andmeasuring platelet aggregation (PA). Clopidogrel and ticlopidine
were equally effective in inhibiting PA, and about 20%of subjects were nonresponders
to each medication. However, only 3.5% were nonresponders to both drugs. This
study suggests that poor responsiveness to clopidogrel is due to a drug-specific mech-
anism, rather than a class effect of thienopyridines. See page 1132. See figure.
Heart Rhythm Disorders
Algorithm May Improve Risk Stratification for ICD Implantation
Currently, most guidelines used to determine eligibility for implantablecardioverter-defibrillator (ICD) implantation rely solely on the measured ejec-
tion fraction (EF). Buxton and colleagues used data from the MUSTT study trial to
examine the risk of total mortality and arrhythmic death associated with 25 variables.
The variables having the greatest prognostic impact were functional class, history of
heart failure, nonsustained ventricular tachycardia not related to bypass surgery, EF,
age, left ventricular conduction abnormalities, inducible sustained ventricular tachy-
cardia, enrollment as an inpatient, and atrial fibrillation. Themodel demonstrates that
patients whose only risk factor is EF 30% have predicted 2-year arrhythmic death
risk 5%. This model suggests that the risk of sudden death is related to multiple
variables and suggests that this risk can be fairly easily calculated. See page 1150.
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Cardiac Imaging
CCTA Predictive of All-Cause Mortality
The prognostic value of identification of coronary artery disease (CAD) by com-puted tomographic coronary angiography (CCTA) has yet to be defined. Min
and colleagues examined the risk of death from all causes byCCTA-defined extent and
severity of CAD in over 1,100 patients. The CCTAmeasurements predictive of death
included stenosis severity in the proximal left anterior descending artery and extent of
CADbynumber of vessels50%and70%stenosis.One-yearmortalitywas 99.7%
for patients with no stenosis 50% versus only 85% for those patients with 50%
stenosis in the left main. In patients presenting with chest pain, CCTA identifies
individuals at increased risk for all-cause death, and a negative CCTA portends an
extremely low risk for death. See page 1161. See figure.
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Cardiac Imaging
Robust Risk Stratification With Dipyridamole CMR
Although cardiac magnetic resonance imaging (CMR) provides excellent spatialresolution, there is little agreement on the best imagingprotocol to predict the risk
of future cardiac events in patients with suspected coronary artery disease (CAD). Bodi
and colleagues reviewed outcomes from 420 patients with chest pain and known or
suspectedCADwho underwent a standardized protocol that calculated the number of
segments of abnormal wall motion at rest (AWM-rest), abnormal wall motion with
dipyridamole (AWM-D), and delayed enhancement. Major adverse cardiac events
were 4 to 5 times more frequent in patients with abnormalities in each of the
parameters, with AWM-D proving the most robust predictor. Dipyridamole stress
CMR appears to be useful for predicting the outcome of patients with known or
suspected CAD. See page 1174. See figure.
Congenital Heart Disease
Percutaneous VSD Closure
Butera and colleagues report their results in 104 patients who underwent percuta-neous closure of a perimembranous ventricular septal defect (pmVSD) using an
Amplatzer VSD device (muscular or eccentric) (AGA Medical Corp., Plymouth,
Minnesota) . The attempt to place a device was successful in 96%of patients whowere
followed for 3 years. No deaths occurred, and the total occlusion rate was 84% at
discharge and 99% during follow-up. A total of 13 early complications occurred
(11.5%), but in all but 2 subjects (1.9%) these were transient and occurred in subjects
6 years old. This study suggests that VSDs can be safely and successfully closed
percutaneously, although caution should be used in those6 years of age, and patients
should be monitored for developing heart block. See page 1189.
